Current topics on low-density lipoprotein apheresis

Therapeutic Apheresis

Volumn 5, Issue 4, 2001, Pages 293-300

  Bambauer, Rolf ^a,b   Schiel, Ralf ^a   Latza, Reinhard ^a  

^a Institute for Blood Purification   (Germany)

^b NONE   (Germany)

Author keywords

Coronary heart disease; Dextran sulfate low density lipoprotein adsorption; Heparin induced extracorporeal low density lipoprotein fibrinogen precipitation; Hyperlipidemia; Immunoadsorption; Low density lipoprotein apheresis; Low density lipoprotein hemoperfusion.

Indexed keywords

DEXTRAN SULFATE; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL;

APHERESIS; ARTICLE; DISEASE SEVERITY; HEART INFARCTION; HEMOPERFUSION; HUMAN; HYPERLIPIDEMIA; IMMUNOADSORPTION; INDUSTRIALIZATION; ISCHEMIC HEART DISEASE; MORTALITY; PRECIPITATION; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; SMOKING;

CORONARY ARTERIOSCLEROSIS; DEXTRAN SULFATE; EXTRACORPOREAL CIRCULATION; HEMOPERFUSION; HUMANS; IMMUNOSORBENT TECHNIQUES; LIPOPROTEINS, LDL; PLASMAPHERESIS;

EID: 0035150546     PISSN: 10916660     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1526-0968.2001.00359.x     Document Type: Article

References (88)

1. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atheroslcerotic coronary artery disease (The PROCAM experience)
2. The Helsinki Heart Study: Coronary heart disease incidence during extended follow-up
3. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
4. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
5. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events trial investigators
6. Design, rational, and baseline characteristics of the prospective pravastatin pooling (PPP) project - A combined analysis of three large-scale randomized trials long-term intervention with pravastatin in ischemic disease (LIPID), cholesterol andrecurrent events (CARE), and West of Scotland coronary prevention study (WOSCOPS)
7. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B(FATS)
8. Oslo diet study and antismoking trial. Results after 102 months
9. The Helsinki Heart Study: Central findings and clinical implications
10. Serum cholesterol, lipoproteins, and the risk of coronary heart disease: The Framingham Study
11. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
12. Low serum cholesterol concentrations and mortality in middle aged British men
13. Persistent problems in the pathogenesis of atherosclerosis
14. Treating hypercholesterolemia: How should practicing physicians interpret thepublished date for patients?
15. Management of hypercholesterolemia: Are preventive interventions advisable?
16. Recommendations of the European Atherosclerosis Society prepared by the international task force for prevention of coronary heart disease. Scientific background and new clinical guidelines
17. How can we best prolong life? Benefits of coronary risk factor reduction in non-diabetic and diabetic subjects
18. Beyond cholesterol
19. Lipoproteins, cells and atheroma formation
20. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependentcoronary vasomotion
21. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease
22. Cholesterol reduction in cardiovascular disease
23. Plasma lipids and lipoproteins and the incidence of cardiovascular disease in the very elderly: The Bronx Aging Study
24. Treatment of lipoproteins in elderly
25. Influence of combined therapy with mevinolin and interruption of bile-acid reabsorption on low desnity lipoprotein in heterozygous familial hypercholesterolemia
26. Portocaval shunt in four patients with homozygous hypercholesterolima
27. Effect of partial heart bypass surgery on mortality and morbidity from coronary heart disease in patients with Report of the Program on the Surgical Control of the Hyperlipidemias
28. Liver transplantation to provide low-density-lipoprotein receptors and lower plasma cholesterol in a child with homozygous familial hypercholesterolemia
29. Treatment of heterozygous familial hypercholesterolemia with lipid-lowering drugs
30. Effect of HELP-LDL apheresis on serum concentrations of human lipoprotein (a): Kinetic analysis of the post-treatment return to baseline levels
31. Three years experience with the liposorber system in hypercholesterolemia
32. LDL apheresis in hypercholesterolemia with the liposorber system and immunoadsorption
33. The HELP-LDL-Apheresis Multicenter Study, an angiographically assessed trial on the role of LDL apheresis in the secondary prevention of coronary heart disease. II. Final evaluation of the effect of regular treatment on LDL-cholesterol plasma concentrations and the course of coronary heart disease
34. LDL apheresis in two patients with extremely elevated lipoprotein(a) levels
35. Treatment of severe hyperlipidemia: Lipid-lowering drugs versus low density lipoprotein-apheresis
36. Four years' treatment of patients with severe hyperlipidemia-lipid lowering drugs versus LDL apheresis
37. Cardiovascular survey methods
38. Formes homozygotes cutaneo-tenineuses de xanthomastose hypercholesterolemique dans une observation familiale exemplaire. Essi de plasmapherese a titre de traitement heroique
39. The role of low-density lipoprotein apheresis in the treatment of familiar hypercholesterolemia
40. Double filtration plasmapheresis with no or minimal amount of blood derivative for substitution
41. Application of specific extracorporeal removal of low density lipoprotein in familial hypercholesterolemia
42. The development of specific plasma immunoabsorption
43. A simple specific method for precipitation of low density lipoproteins
44. Clinical thermofiltration: Initial application
45. A new low density lipoprotein apheresis system using two dextran sulfate cellulose columns in an automated column regeneraing unit (LDL-continuous apheresis)
46. Lipid apheresis by hemoperfusion: In vitro efficacy and ex vivo bio-compatibility of a new low-density lipoprotein adsorber compatible with human whole blood
47. Results of an open, longitudinal multicenter LDL-apheresis trial
48. Immunosorbent for selective removal of lipoprotein (a) from human plasma: In vitro study
49. Extracorporeal Immunoadsorption for the specific removal of lipoprotein (a) (Lp(a) apheresis): Preliminary clinical data
50. Lipoprotein (a) apheresis in severe coronary heart disease: An immunoadsorption method
51. The HELP-LDL-apheresis multicenter study, an angiographically assessed trial on the role of LDL-apheresis in the secondary prevention of coronary heart disease. I: Evaluation of safety and cholesterol-lowering effects during the first 12 months
52. Aggressive lowering of fibrinogen and cholesterol in the prevention of graft vessel disease after heart transplantation
53. Assessment of the biocompatibility and long-term effect of LDL-apheresis by dextran sulfate-cellulose column
54. Apheresis technology for prevention and regression of atherosclerosis: An overview
55. LDL apheresis using the Liposorber LA-15 system in coronary and peripheral vascular disease associated with severe hypercholesterolemia
56. LDL-hemoperfusion: A new procedure for LDL-apheresis: First clinical application of an LDL adsorber compatible with whole human Blood
57. LDL-hemoperfusion - A new procedure for LDL-apheresis: Biocompatibility results from a first pilot study in hypercholesterolemic atherosclerosis patients
58. Direct adsorption of lipoproteins (DALI) from whole blood: First long-term clinical experience with a new LDL-apheresis system for the treatment of familial hypercholesterolemia
59. Up-regulation of LDL-immunoapheresis in patients with familial hypercholesterolemia
60. Cardiovascular medicine at the turn of the milenium: Triumphs, concerns and oportunitis
61. Safety and effetiveness of long-term LDL-apheresis in patients at high risk
62. Long-term eficiency, biocompatibility, and clinical safety of combined simultaneous LDL-apheresdis and hemodialysis in patients with hypercholesterolemia and end-stage renal failure
63. Improvement of coronary vasodilatation capacity through single LDL apheresis
64. Low-density lipoprotein (LDL) oxidizability before and after LDL apheresdis
65. Acute effect of HELP treament on radical scavering enzyme activities, total glutathione concentrations in granulocytes, and selenium in plasma
66. Heparin-mediated extracorporeal LDL/fibrinogen precipitation-HELP-in coronary and cerebral ischemia
67. Clinical utility of LDL-apheresis in the treatment of sudden hearing loss: A prospective, randomized study
68. Treatment of refractory familial hypercholesterolemia by low-density lipoprotein apheresis using an automated dextran sulfate cellulose adsorption system
69. Prevention of restenosis after percutaneous transluminal coronary angioplasty by reducing lipoprotein (a) levels with low-density lipoprotein apheresis
70. LDL-apheresis Atherosclerosis Regression study (LAARS). Effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis
71. Clinical experience and future directions for low-density lipoprotein apheresis in the United States
72. Low-density lipoprotein apheresis for prevention and regression of atherosclerosis: Clinical results
73. Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia
74. Effects of intensive lipid lowering by low-density lipoprotein apheresis on regression of coronary atherosclerosis in patients with familial hypercholesterolemia: Japan low-density lipoprotein apheresis coronary athererosclerosis athereroselerosis prospective study (L-CAPS)
75. Evaluation of microparticles released from an adsorber used for low density lipoprotein apheresis
76. Microparticles released from adsorber columns used for LDL-apheresis
77. Anaphylactoid reactions. LDL-apheresis with dextran sulphate, and ACE inhibitors
78. ACE inhibitors and LDL-apheresis with dextran sulfate adsorption
79. LDL-apheresis with dexran sulfate and anaphylactoid reaction to ACE inhibitors
80. Plasma cholesterol concentration and mortality. The Whitehall Study
81. Influence of low density lipoproteins (LDL) on the reactivity of atherosclerotic arteries
82. LDL-apheresis as long-term treatment in severe hyperlipidemia using differing methods
83. The mysteries of lipoprotein(a)
84. Lipoprotein(a)
85. Lipoprotein(a). Heterogenecity and biological relevance